Santen Pharmaceutical Co., Ltd. (OTCMKTS:SNPHY) Sees Significant Increase in Short Interest

Santen Pharmaceutical Co., Ltd. (OTCMKTS:SNPHY) was the recipient of a large increase in short interest during the month of February. As of February 15th, there was short interest totalling 11,000 shares, an increase of 32.5% from the January 31st total of 8,300 shares. Based on an average daily trading volume, of 17,500 shares, the days-to-cover ratio is currently 0.6 days.

Santen Pharmaceutical Stock Performance

Santen Pharmaceutical stock traded up $0.13 during mid-day trading on Wednesday, hitting $9.38. 2,288 shares of the company were exchanged, compared to its average volume of 12,600. Santen Pharmaceutical has a 12-month low of $8.65 and a 12-month high of $13.00. The business’s 50 day simple moving average is $9.75 and its two-hundred day simple moving average is $11.00.

About Santen Pharmaceutical

Santen Pharmaceutical Co, Ltd. engages in the research and development, manufacture, and marketing of pharmaceuticals and medical devices in Japan and internationally. Its product portfolio includes tafluprost/timolol maleate, a prostaglandin F2a derivative and a beta-adrenergic receptor blocker; and netarsudil mesilate and latanoprost, a prostaglandin F2a derivative which is marketing approval phase for the treatment of glaucoma and ocular hypertension.